Liqun Zhao

FDA investigator

Appears on 4 documents from 2024 to 2025, most often at sites in Ireland. Most often cites production record review (21 CFR 211.192).

4
Documents on file
4.3
Observations per 483
2024
First seen
2025
Most recent

What they cite most

From 16 observations

Activity by year

2024: 3, 2025: 1

Where

Ireland 1 · Lithuania 1 · Maryland 1 · Singapore 1

Is Liqun Zhao coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

4 documents, newest first
FirmOpen
483 Wuxi Biologics Ireland Limited Dundalk Science and Technology ParkDec 16, 2025 · Mullagharlin, Ireland
483 AstraZeneca Pharmaceuticals LP Frederick Manufacturing Cente /'Jun 7, 2024 · Frederick, Maryland
483 Amgen Singapore Manufacturing Pte. Ltd.May 14, 2024 · Singapore, Singapore
483 BIOTECHPHARMA BIOTECHNOLOGINES FARMACIJOS CENTRAS UABJan 31, 2024 · Vilnius, Lithuania

About this profile

What does Liqun Zhao inspect?

Liqun Zhao appears on 4 documents on file covering 4 sites, most often in Ireland.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.113 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Liqun Zhao is dated Dec 16, 2025.